HilleVax, Inc.: restructuring charge — HilleVax cuts 41 employees (~40% workforce); expects $3.4M in severance charges

HilleVax, Inc.

Workforce reduced by ~41 employees (40%) to lower operating expenses while preserving core capabilities.
Estimated severance and related charges of $3.4M, majority expected in Q3 2024.
Company will explore continued development of HIL-214 and HIL-216 norovirus vaccine candidates and business development.
Workforce reduction approved by board on July 26, 2024; substantial completion in Q3 2024.
Risks include inability to realize expected cash savings, retain key personnel, or find development path for pipeline candidates.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.99

HilleVax, Inc. announced a restructuring with charges of workforce reduction of approximately 41 employees affecting entire company (approximately 41 employees, constituting approximately 40% of the Company’s workforce).

Type: restructuring
Charge: workforce reduction of approximately 41 employees
Affected area: entire company
Headcount: approximately 41 employees, constituting approximately 40% of the Company’s workforce

Exact text from the filing

On July 31, 2024, HilleVax, Inc. (the “Company”) announced a workforce reduction of approximately 41 employees, constituting approximately 40% of the Company’s workforce.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0000950170-24-088549

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.